The adoption of new, surrogate endpoints in clinical research provides a means to balance the need for timely patient access to innovative medicines without delays caused by using long-term survival endpoints with the means to measure clinical value for adjuvant and neoadjuvant therapies and allowing for the comparison of trials across multiple dimensions.

This webinar follows the release of a new IQVIA Institute report on Evolving Oncology Endpoints and will include panelists from a variety of disciplines.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.